Palvella posts updated corporate presentation; no material new disclosures

PALVELLA THERAPEUTICS, INC.

Filed an 8-K under Item 7.01 furnishing a corporate presentation dated September 2025.
Presentation describes first-in-disease therapies for rare genetic skin diseases.
No financial results, pipeline updates, or guidance changes disclosed in the filing.
Presentation will be used in investor meetings going forward.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.